Canaccord Genuity Maintains Buy on Enovis, Lowers Price Target to $42

Benzinga · 1d ago
Canaccord Genuity analyst Caitlin Cronin maintains Enovis (NYSE:ENOV) with a Buy and lowers the price target from $45 to $42.